Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Richard

Showing results (171-180 of 195) with videos related to

Pageof 20
Sort By:
Biorxiv : the Preprint Server for Biology|January 4, 2022
Temporal associations of B and T cell immunity with robust vaccine responsiveness in a 16-week interval BNT162b2 regimenManon Nayrac, Mathieu Dubé, Gérémy Sannier, et al.
Cell Host & Microbe|May 21, 2021
Modulating HIV-1 envelope glycoprotein conformation to decrease the HIV-1 reservoirJyothi K Rajashekar, Jonathan Richard, Jagadish Beloor, et al.
Biorxiv : the Preprint Server for Biology|August 10, 2021
Structural Basis and Mode of Action for Two Broadly Neutralizing Antibodies Against SARS-CoV-2 Emerging Variants of ConcernWenwei Li, Yaozong Chen, Jérémie Prévost, et al.
Medrxiv : the Preprint Server for Health Sciences|August 30, 2023
Plasmatic HIV-1 soluble gp120 is associated with immune dysfunction and inflammation in ART-treated individuals with undetectable viremiaMehdi Benlarbi, Jonathan Richard, Catherine Bourassa, et al.
The Journal of Infectious Diseases|November 30, 2023
Plasma Human Immunodeficiency Virus 1 Soluble Glycoprotein 120 Association With Correlates of Immune Dysfunction and Inflammation in Antiretroviral Therapy-Treated Individuals With Undetectable ViremiaMehdi Benlarbi, Jonathan Richard, Catherine Bourassa, et al.
Biorxiv : the Preprint Server for Biology|September 10, 2024
The asymmetric opening of HIV-1 Env by a potent CD4 mimetic enables anti-coreceptor binding site antibodies to mediate ADCCJonathan Richard, Michael W Grunst, Ling Niu, et al.
Microbiology Spectrum|June 22, 2022
Correction for Valcourt et al., "Evaluating Humoral Immunity against SARS-CoV-2: Validation of a Plaque-Reduction Neutralization Test and a Multilaboratory Comparison of Conventional and Surrogate Neutralization Assays"Emelissa J Valcourt, Kathy Manguiat, Alyssia Robinson, et al.
Cell Reports|February 26, 2022
SARS-CoV-2 Omicron Spike recognition by plasma from individuals receiving BNT162b2 mRNA vaccination with a 16-week interval between dosesDebashree Chatterjee, Alexandra Tauzin, Lorie Marchitto, et al.
Cell Reports|October 16, 2022
A boost with SARS-CoV-2 BNT162b2 mRNA vaccine elicits strong humoral responses independently of the interval between the first two dosesAlexandra Tauzin, Shang Yu Gong, Debashree Chatterjee, et al.
Cell Reports|June 22, 2022
Temporal associations of B and T cell immunity with robust vaccine responsiveness in a 16-week interval BNT162b2 regimenManon Nayrac, Mathieu Dubé, Gérémy Sannier, et al.
Pageof 20

Showing results (171-180 of 195) with videos related to

Sort By:
Pageof 20
Biorxiv : the Preprint Server for Biology|January 4, 2022
Temporal associations of B and T cell immunity with robust vaccine responsiveness in a 16-week interval BNT162b2 regimenManon Nayrac, Mathieu Dubé, Gérémy Sannier, et al.
Cell Host & Microbe|May 21, 2021
Modulating HIV-1 envelope glycoprotein conformation to decrease the HIV-1 reservoirJyothi K Rajashekar, Jonathan Richard, Jagadish Beloor, et al.
Biorxiv : the Preprint Server for Biology|August 10, 2021
Structural Basis and Mode of Action for Two Broadly Neutralizing Antibodies Against SARS-CoV-2 Emerging Variants of ConcernWenwei Li, Yaozong Chen, Jérémie Prévost, et al.
Medrxiv : the Preprint Server for Health Sciences|August 30, 2023
Plasmatic HIV-1 soluble gp120 is associated with immune dysfunction and inflammation in ART-treated individuals with undetectable viremiaMehdi Benlarbi, Jonathan Richard, Catherine Bourassa, et al.
The Journal of Infectious Diseases|November 30, 2023
Plasma Human Immunodeficiency Virus 1 Soluble Glycoprotein 120 Association With Correlates of Immune Dysfunction and Inflammation in Antiretroviral Therapy-Treated Individuals With Undetectable ViremiaMehdi Benlarbi, Jonathan Richard, Catherine Bourassa, et al.
Biorxiv : the Preprint Server for Biology|September 10, 2024
The asymmetric opening of HIV-1 Env by a potent CD4 mimetic enables anti-coreceptor binding site antibodies to mediate ADCCJonathan Richard, Michael W Grunst, Ling Niu, et al.
Microbiology Spectrum|June 22, 2022
Correction for Valcourt et al., "Evaluating Humoral Immunity against SARS-CoV-2: Validation of a Plaque-Reduction Neutralization Test and a Multilaboratory Comparison of Conventional and Surrogate Neutralization Assays"Emelissa J Valcourt, Kathy Manguiat, Alyssia Robinson, et al.
Cell Reports|February 26, 2022
SARS-CoV-2 Omicron Spike recognition by plasma from individuals receiving BNT162b2 mRNA vaccination with a 16-week interval between dosesDebashree Chatterjee, Alexandra Tauzin, Lorie Marchitto, et al.
Cell Reports|October 16, 2022
A boost with SARS-CoV-2 BNT162b2 mRNA vaccine elicits strong humoral responses independently of the interval between the first two dosesAlexandra Tauzin, Shang Yu Gong, Debashree Chatterjee, et al.
Cell Reports|June 22, 2022
Temporal associations of B and T cell immunity with robust vaccine responsiveness in a 16-week interval BNT162b2 regimenManon Nayrac, Mathieu Dubé, Gérémy Sannier, et al.
Pageof 20